Santen Pharmaceutical Co., Ltd. (TYO:4536)

Market Cap	573.22B +16.5%
Revenue (ttm)	287.99B -4.6%
Net Income	30.60B +11.3%
EPS	91.84 +18.7%
Shares Out	321.67M
PE Ratio	19.40
Forward PE	16.48
Dividend	38.00 (2.11%)
Ex-Dividend Date	Mar 30, 2026

Volume	973,800
Average Volume	1,024,390
Open	1,786.50
Previous Close	1,782.00
Day's Range	1,772.00 - 1,802.50
52-Week Range	1,342.50 - 1,939.00
Beta	0.28
RSI	49.73
Earnings Date	May 8, 2026

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4536

Financial Performance

In fiscal year 2025, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.